X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES VENUS REMEDIES JUBILANT LIFE SCIENCES/
VENUS REMEDIES
 
P/E (TTM) x 12.2 -0.9 - View Chart
P/BV x 1.7 0.1 2,536.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   VENUS REMEDIES
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-18
VENUS REMEDIES
Mar-18
JUBILANT LIFE SCIENCES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,039126 825.3%   
Low Rs60061 982.0%   
Sales per share (Unadj.) Rs482.6301.8 159.9%  
Earnings per share (Unadj.) Rs40.7-24.9 -163.7%  
Cash flow per share (Unadj.) Rs67.42.5 2,647.4%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs262.3293.3 89.4%  
Shares outstanding (eoy) m155.7912.34 1,262.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.70.3 548.1%   
Avg P/E ratio x20.1-3.8 -535.3%  
P/CF ratio (eoy) x12.236.7 33.1%  
Price / Book Value ratio x3.10.3 980.0%  
Dividend payout %7.40-   
Avg Mkt Cap Rs m127,6701,154 11,065.3%   
No. of employees `0002.40.9 263.4%   
Total wages/salary Rs m15,559393 3,958.0%   
Avg. sales/employee Rs Th30,861.44,026.1 766.5%   
Avg. wages/employee Rs Th6,387.0425.0 1,502.9%   
Avg. net profit/employee Rs Th2,604.4-331.8 -785.0%   
INCOME DATA
Net Sales Rs m75,1783,724 2,018.7%  
Other income Rs m40023 1,779.1%   
Total revenues Rs m75,5793,747 2,017.3%   
Gross profit Rs m15,184395 3,845.9%  
Depreciation Rs m4,151338 1,226.9%   
Interest Rs m2,843354 802.4%   
Profit before tax Rs m8,591-275 -3,120.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,24732 7,109.5%   
Profit after tax Rs m6,344-307 -2,067.2%  
Gross profit margin %20.210.6 190.5%  
Effective tax rate %26.2-11.5 -227.8%   
Net profit margin %8.4-8.2 -102.4%  
BALANCE SHEET DATA
Current assets Rs m31,8982,638 1,209.3%   
Current liabilities Rs m20,0472,305 869.8%   
Net working cap to sales %15.88.9 176.3%  
Current ratio x1.61.1 139.0%  
Inventory Days Days68135 49.9%  
Debtors Days Days5546 118.5%  
Net fixed assets Rs m60,7154,871 1,246.5%   
Share capital Rs m156123 126.3%   
"Free" reserves Rs m40,7103,496 1,164.6%   
Net worth Rs m40,8653,619 1,129.2%   
Long term debt Rs m30,4781,374 2,217.6%   
Total assets Rs m96,1767,509 1,280.9%  
Interest coverage x4.00.2 1,803.8%   
Debt to equity ratio x0.70.4 196.4%  
Sales to assets ratio x0.80.5 157.6%   
Return on assets %9.60.6 1,513.1%  
Return on equity %15.5-8.5 -183.1%  
Return on capital %16.01.6 1,013.0%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m14,4020-   
Fx outflow Rs m12,044517 2,331.8%   
Net fx Rs m2,358-517 -456.5%   
CASH FLOW
From Operations Rs m13,032514 2,533.4%  
From Investments Rs m-6,177-123 5,017.9%  
From Financial Activity Rs m-9,011-387 2,327.9%  
Net Cashflow Rs m-2,1234 -50,538.1%  

Share Holding

Indian Promoters % 45.6 32.9 138.8%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 0.2 4,833.3%  
FIIs % 21.2 0.6 3,655.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 66.4 31.8%  
Shareholders   23,815 20,121 118.4%  
Pledged promoter(s) holding % 15.9 36.4 43.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Jul 19, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - PLETHICO PHARMA COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS